{"name":"Kedrion S.p.A.","slug":"kedrion-s-p-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Coagadex(R)","genericName":"Coagadex(R)","slug":"coagadex-r","indication":"Congenital Factor X deficiency","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Human Plasminogen","genericName":"Human Plasminogen","slug":"human-plasminogen","indication":"Acute ischemic stroke","status":"phase_2"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Kedbumin 25%","genericName":"Kedbumin 25%","slug":"kedbumin-25","indication":"Hypoproteinemia and hypovolemia in critically ill patients","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Kedrion IVIG 10%","genericName":"Kedrion IVIG 10%","slug":"kedrion-ivig-10","indication":"Primary immunodeficiency disorders","status":"phase_3"}]}],"pipeline":[{"name":"Coagadex(R)","genericName":"Coagadex(R)","slug":"coagadex-r","phase":"phase_3","mechanism":"Coagadex is a recombinant human vitamin K-dependent clotting factor X that replaces deficient or dysfunctional Factor X to restore blood coagulation.","indications":["Congenital Factor X deficiency","Acquired Factor X deficiency"],"catalyst":""},{"name":"Human Plasminogen","genericName":"Human Plasminogen","slug":"human-plasminogen","phase":"phase_2","mechanism":"Activates plasminogen to break down blood clots","indications":["Acute ischemic stroke","Pulmonary embolism"],"catalyst":""},{"name":"Kedbumin 25%","genericName":"Kedbumin 25%","slug":"kedbumin-25","phase":"marketed","mechanism":"Kedbumin 25% is a human serum albumin solution that restores and maintains oncotic pressure and serves as a carrier protein for endogenous and exogenous substances in the bloodstream.","indications":["Hypoproteinemia and hypovolemia in critically ill patients","Acute blood loss and hemorrhagic shock","Severe burns","Liver cirrhosis with ascites","Nephrotic syndrome"],"catalyst":""},{"name":"Kedrion IVIG 10%","genericName":"Kedrion IVIG 10%","slug":"kedrion-ivig-10","phase":"phase_3","mechanism":"Kedrion IVIG 10% is an intravenous immunoglobulin preparation that provides passive immunity by supplying pooled human antibodies to modulate immune responses and neutralize pathogens.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency (e.g., in hematologic malignancies)","Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5wNzVQbHdzN1l0ZHd6NnB4djdqU1FCeUY5RXNSblhVcW8wcURTZ3NxMVp6V2tkdmRwaVc5VHBvTG5RYjc5a2VsenFrQlVPQUc3QjUwcGhEVG9UMkc5UGJxMVRzcFpKY2hYY0F1dlV6T2tPZmdnUmdfRjdjbng?oc=5","date":"2026-03-16","type":"pipeline","source":"Fortune Business Insights","summary":"US Immunoglobulin Market Size, Share | Industry Report [2034] - Fortune Business Insights","headline":"US Immunoglobulin Market Size, Share | Industry Report [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOSm1VYktUZ3Q3SmtqaUNmNURMazBGUWNIOEVDclkxX2EtLVNzUGtaM3JHRFIwWnlCejF2YWtZTVQwdG44bWJxZzdjYmI0TE85VnJ2R1JYTk1sSHdDVUpqREpfM194U3c1NnBGNTE1TFdCb3NOQnRqbWFvcUphS3J4eGlHT253VVRQ?oc=5","date":"2025-07-25","type":"pipeline","source":"Insightace Analytic","summary":"Myasthenia Gravis Treatment Market Latest Research Report 2025-2034 - Insightace Analytic","headline":"Myasthenia Gravis Treatment Market Latest Research Report 2025-2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE93d2dfVEYxOVdCXzlUTU11aE9KUzFiS1AwTHBxRUR0czRvaUUyMmxUOUp1UEhLdXRYQVVBVlhYbUlwWmhGaEZDLTNWelVsOWx5MGtXOVcxSzZ2Z0tRN0R6UXFPWU9OSHByd3djek0yTkE5TE1lYl9PdW1kSG1IQQ?oc=5","date":"2025-05-19","type":"pipeline","source":"Fortune Business Insights","summary":"Coagulation Factors Market Size, Share, Analysis | Report [2034] - Fortune Business Insights","headline":"Coagulation Factors Market Size, Share, Analysis | Report [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNVzY1SWNCMGw2SmphdUQ5U3RTbkJVQkdvOTBNVVNLQ2hicjRkU2lPMGctQ2diZUJJOExaTVVyVEJwX1JhM21rTGtZaDNmcUwwTTg5Y1d3bHFnTnBRbW9wel9FemFsNEJZQ25YS0xLSW5aZEFIbFhPMy1rVGxjbHh2X2JVTkZvRlVCNmliZDBqNnEzdk5JZFVjQXktekk?oc=5","date":"2023-10-13","type":"pipeline","source":"openPR.com","summary":"Plasma Expander Market to See Booming Growth 2023-2030 | Hikma - openPR.com","headline":"Plasma Expander Market to See Booming Growth 2023-2030 | Hikma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPRFptQjcwVV9kMURFMkItRmViNTVRTER5NzhVTktzTVprNXp1YkNfZENDZktSSW9FNWRyZDBYZkxob245a3U1akZGNjZUSjg3SVlhY25lMlBPc0tOcktCdVdlXzhab2tSaVdvZzBLcDZtdlJQRWVlc2FXclJJZHB4clQ3TmRFYXo5Qnprb0tVZ2hRQWt1Z0tKc0Y5VnlGWTVsWGlxMXlVNWM4NEQ2b0RxVDVyYmp4MVlBTUpNa3JmeTZfQQ?oc=5","date":"2022-08-01","type":"deal","source":"BeBeez International","summary":"FSI to buy a 35% stake in Sterling as capital increase for supporting the pharma company growth - BeBeez International","headline":"FSI to buy a 35% stake in Sterling as capital increase for supporting the pharma company growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFBROElRcWxPSV9rQmtrbHRHQkV0YUxvNlFZQ1BrNWVnelR6UnRGS2ZySTN3b3J4NEVKVkxWcGtxTHZBWU5rWllUVjgxTFg4a3dqeC1HdklpbnRUN3lVVDF0ZExqZzJBQ1NtdXRyWVZYbw?oc=5","date":"2022-07-26","type":"pipeline","source":"Straits Research","summary":"Plasma Fractionation Market Size, Share & Trends | Industry Report, 2033 - Straits Research","headline":"Plasma Fractionation Market Size, Share & Trends | Industry Report, 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5rQ3RJbzdIU0dQbnp3WGFXRjEtVE5qcTVmUS1QYUdmZ2lqZVFJbWxZVVNzd3B3WV9udVFVQnE1X2lCNGRpSlhTRXhXTHlHMWRSVW0waG45UnN6X2phaWZCMV9hUF95WFc5dWVQcVRQNGlRT2NCY2FvbVFOMNIBgAFBVV95cUxOdTNYMVpTMVI4R19CajV4WjE0SS1TOW1JTWo0b1l5OXNqRFQ0cVF2WkFuX2VjYTZoblJUMm1FWGQxcUw2bVlSME9aNGVvb1NEMXk1UElzUlE5UnpBaG5mT1pLYjMzcHB2eC0yQjkyRjlKbjdORFZBNkM2cE40bmlSZw?oc=5","date":"2022-02-16","type":"pipeline","source":"Romania Insider","summary":"Romanian competition body fines five European pharma companies on collusion - Romania Insider","headline":"Romanian competition body fines five European pharma companies on collusion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxOczlGRldJdG1oOEpETWFOc3lQaGdOODhRa3ZMT0dvN2lTU2NUOGhkM2VWZXpDd3hDLTM0aGpoZXdsWS05SDdBM1RrQ3JyMDMza0NPNy1nYVUtaXdjUmtfUWlNUnU1RnpYSkZxY2t3SzRjRmZRM0ZHbzU4QnY5VFBBTVhyaXRRVXc2ME45Rmk5ZWZzdThpS1JTQ1o3OFB1RmNiMkJadGczWXR3VmthTjg2TXZCYjB2b2Q4b3gtQkx1cldieDFPR2NrWm9QODA5MVAyTHVPXzM1Z3ZqOUp1aVBBM3RRVlRpcjRmcjZOUkFzcEVBMkVrcm9tY0RDa3pSaDRyMU5wZHFUcHEtVk04VXdocmQ4My1IRGk1TG85aVFDOU4zS1phYVpwaF9LOGtQYXZtSHNvSmpsUXdDMGxOcXNUdE5wTzJCMjg?oc=5","date":"2022-01-21","type":"deal","source":"BeBeez International","summary":"It’s official, Permira strikes control of leading plasma derivatives maker Kedrion and British competitor BPL. Together with ADIA. The Marcucci family and FSI fund to reinvest in the deal. Cdp Equity ","headline":"It’s official, Permira strikes control of leading plasma derivatives maker Kedrion and British competitor BPL. Together ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNYXM2YmRLaW1mT1JzdTFIZC1hZEs2LVRyaTZfUWl0VUY2VUhLNGEyZWtmaFI2MW1BMkJjRmRXSkJtVVNmNHo4MVowNXpsaGpENWFpdnNONE9XTFJLV0ZRbjhXbHRYdE5TcjctVUlnRXU4MEdhMDNZWFdZLUc1WnBZR3Zad3VGbng0Q3Z4azNvTVNvQQ?oc=5","date":"2020-10-06","type":"pipeline","source":"PR Newswire","summary":"Kedrion Names Val Romberg As CEO - PR Newswire","headline":"Kedrion Names Val Romberg As CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPV0hZaUFfUHFoWlRickl1UVpUWXptdFVPWEU4TUxrdkhraklORWR4azJLWXRMOGlqR1B2bk9GVWRqd1BBbXB1aTIyNmw1V3Yza3I3YXZKb1NiT1YyVjZCVDY1OGVZVkpHV0RrR3lVeUNBcGphT2VROHhGZEFfSlpNZ3h3Zm1sQmppNTBVUlVDMEVSb19TUnc?oc=5","date":"2019-11-08","type":"pipeline","source":"Fortune Business Insights","summary":"Plasma Fractionation Market Size, Share | Global Report [2034] - Fortune Business Insights","headline":"Plasma Fractionation Market Size, Share | Global Report [2034]","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":2,"phase_2":1,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}